Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise

The nomination of VENT-03 validates Ventus’ proprietary ReSOLVE TM drug discovery platform Phase 1 clinical trials will include patients with multiple distinct interferonopathies Robust analyses based on internally developed and validated skin and blood biomarkers will measure inflammation and target engagement in distinct diseases, de-risking late-stage development WALTHAM, Mass. & MONTREAL — Jan. 4, 2023 — (BUSINESS WIRE) — Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today the nomination of a potential first-in-class cGAS inhibitor, VENT-03, as the company’s first development candidate directed against cGAS. This represents the third development candidate nominated in the past 12 months to Ventus’ pipeline, following the nominations of VENT-02, a brain-penetrant NLRP3 inhibitor, and VENT-01, a peripherally restricted NLRP3 inhibitor that is partnered with Novo Nordisk. cGAS activation leads to a type I interferon response, which is implicated in a broad range of diseases, including cutaneous lupus erythematosus, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis, as well as neuroinflammatory and neurodegenerative diseases. In addition, genetic diseases, such as severe infant onset Aicardi-Goutières Syndrome and genetic forms of chilblain lupus, are driven by genetic mutations that lead to the activation of the pathway in humans. In disease-relevant preclinical studies, VENT-03 demonstrated robust in vivo pharmacodynamic activity and efficacy. “cGAS is a highly coveted target for pro-inflammatory and neurodegenerative diseases for which no inhibitor has advanced into clinical development to date, despite significant efforts from the drug discovery industry over the past decade,” said Ventus’ President and CEO Marcelo Bigal, M.D., Ph.D. “We expect VENT-03 to be the first cGAS inhibitor to enter the clinic, with a clinical development plan tailored to provide multiple data readouts prior to Phase 2 trials.” In December 2022, Ventus scientists published a state-of-the-art review on the industry’s progress to develop inhibitors in the cGAS-STING pathway. In May 2022, Ventus announced that it had been awarded a Lupus Research Program Idea Award from the U.S. Department of Defense, and, along with it, a multi-year grant to study the role of cGAS in lupus and the potential for treatment of the disease using a cGAS inhibitor. “The nomination of VENT-03 as our first development candidate targeting cGAS was made possible by the unique insights provided by ReSOLVE, our proprietary drug discovery platform,” said Ventus’ Chief Scientific Officer Michael Crackower, Ph.D. “After identifying a high-resolution co-crystal structure of cGAS that was different from what had been previously published, we used ReSOLVE to determine characteristics of the binding pocket that are unique to only some of the target’s many conformations, a major breakthrough that transformed our ability to achieve high potency in our cGAS inhibitors. Given the highly validated role of the cGAS pathway as a driver of disease, we are now developing additional cGAS inhibitors to achieve the full potential of this attractive target in distinct therapeutic areas.” About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. dsDNA in the cytoplasm is generally associated with cellular dysfunction, as seen in multiple diseases such as cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE) and dermatomyositis (DM). cGAS activation leads to cGAMP formation, activation of STING and downstream expression of type I interferons such as IFN-α, -ß and -κ, leading to pronounced inflammation and tissue damage. This pathway also leads to the expression of several other proinflammatory cytokines such as CXCL10. Genetic mutations that lead to the aberrant activation of cGAS/STING in humans are known to cause severe infant onset Aicardi-Goutières Syndrome (AGS) and genetic forms of chilblain lupus, demonstrating the relevance of the pathway in human diseases. Given that the pathophysiology and presentation of these genetic diseases have significant similarities with idiopathic complex diseases such as CLE, SLE and DM, these diseases represent highly compelling opportunities for treatment with a cGAS inhibitor. About Ventus Therapeutics Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company’s proprietary drug discovery platform ReSOLVE gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated small molecule medicines. The Company’s lead programs target key innate immune modulators, including NLRP3 and cGAS. The Company is using its ReSOLVE platform to improve the way medicines are discovered and developed, with the ultimate goal of restoring the health of people facing serious illnesses. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of the executive leadership team, Ventus’ business strategy, current programs, future results of operations, and financial position. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business and its efforts to address the impact on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers and manufacturers; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact Kyle Evans ICR Westwicke 646-277-1295 [email protected] © 2026 Ventus Therapeutics. All Rights Reserved. Explore About Pipeline Platform Patients News & Events Careers Viewpoints Contact For general inquiries - [email protected] For medical inquiries - [email protected] USA 100 Beaver St, Suite 201 Waltham, Massachusetts 02453 Canada 4800, rue Lévy # 110 Saint-Laurent, H4R 2P1, QC, Canada Follow Us Legal Privacy Policy Cookie Policy click click MENU About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Viewpoints À propos Aperçu Direction Conseil d’administration Fondateurs Consultants Investisseurs Filiere de Developpement Filiere de Developpement VENT-03 VENT-02 VENT-04 Plateforme Essais cliniques Actualités et événements Dernières Nouvelles événements Dans les médias Emplois Aperçu Postes Vacants Points de vue We are using cookies to give you the best experience on our website. To find out more about the information we collect, please review our Privacy Policy . You can find out more about which cookies we are using or switch them off in settings . Nous utilisons des témoins pour vous offrir la meilleure expérience possible sur notre site Web. Pour en savoir plus sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Vous y trouverez de plus amples renseignements sur les témoins que nous utilisons, ou vous pouvez les désactiver dans les paramètres . Accept / Accepter Settings / Paramètres Close GDPR Cookie Settings Privacy Overview / Généralités sur la confidentialité Strictly Necessary Cookies / Témoins strictement nécessaires 3rd Party Cookies / Témoins tiers Powered by GDPR Cookie Compliance Privacy Overview / Généralités sur la confidentialité This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. To find out more about the information we collect, please review our Privacy Policy . Nous utilisons des témoins afin de vous offrir la meilleure expérience utilisateur possible sur notre site Web. Les informations contenues dans les fichiers témoins sont stockées dans votre navigateur. Elles servent entre autres à vous reconnaître lorsque vous revenez sur notre site Web et à nous aider à déterminer quelles sections du site vous intéressent le plus ou vous sont les plus utiles. Pour en savoir davantage sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Strictly Necessary Cookies / Témoins strictement nécessaires Strictly Necessary Cookies should be enabled at all times so that we can save your preferences for cookie settings. Les témoins strictement nécessaires doivent être activés en tout temps pour que vos préférences concernant les paramètres des témoins puissent être enregistrées. Enable or Disable Cookies Enabled Disabled 3rd Party Cookies / Témoins tiers This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Ce site Web utilise Google Analytics pour collecter des informations anonymes telles que le nombre de visiteurs sur le site et les pages les plus populaires. En maintenant ces témoins activés, vous nous aidez à améliorer notre site Web. Enable or Disable Cookies Enabled Disabled Enable All / Activer tout Reject All / Refuser tout Save Changes / Enregistrer les modifications

The release as fetched from its publisher. ventustx.com ↗